Mixed-methods evaluation of a behavioural intervention package to identify and amend incorrect penicillin allergy records in UK general practice
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ..
OBJECTIVES: About 6% of the UK general practice population has a record of a penicillin allergy but fewer than 10% of these are likely to be truly allergic. In the ALABAMA (Allergy Antibiotics and Microbial resistance) feasibility trial, primary care patients with penicillin allergy were randomised to penicillin allergy assessment pathway or usual care to assess the effect on health outcomes. A behavioural intervention package was developed to aid delabelling. This study aimed to investigate patients' and clinicians' views of penicillin allergy testing (PAT).
DESIGN: We conducted a mixed-methods process evaluation embedded within the ALABAMA trial, which included a clinician survey, a patient survey (at baseline and follow-up) and semistructured interviews with patients and clinicians.
SETTINGS: The study was conducted in primary care, as part of the feasibility stage of the ALABAMA trial.
PARTICIPANTS: Patients and primary care clinicians.
RESULTS: Clinicians (N=53; 52.2%) were positive about PAT and its potential value but did not have previous experience of referring patients for a PAT and were unsure whether patients would take penicillin after a negative allergy test. Patients (N=36; 46%) were unsure whether they were severely allergic to penicillin and did not fear a severe allergic reaction to penicillin. Clinician interviews showed that they were already aware of the benefit of PAT. Interviews with patients suggested the importance of safety as patients valued having numerous opportunities to address their concerns about safety of the test.
CONCLUSIONS: This study highlights the positive effects of the ALABAMA behavioural intervention for both patients and clinicians.
TRIAL REGISTRATION NUMBER: NCT04108637; ISRCTN20579216; Pre-results.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
BMJ open - 12(2022), 6 vom: 03. Juni, Seite e057471 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wanat, Marta [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 25.01.2023 Date Revised 20.11.2023 published: Electronic ClinicalTrials.gov: NCT04108637 ISRCTN: ISRCTN20579216 Citation Status MEDLINE |
|---|
| doi: |
10.1136/bmjopen-2021-057471 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352019247 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352019247 | ||
| 003 | DE-627 | ||
| 005 | 20231226205855.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmjopen-2021-057471 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1173.xml |
| 035 | |a (DE-627)NLM352019247 | ||
| 035 | |a (NLM)36691248 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wanat, Marta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mixed-methods evaluation of a behavioural intervention package to identify and amend incorrect penicillin allergy records in UK general practice |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.01.2023 | ||
| 500 | |a Date Revised 20.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04108637 | ||
| 500 | |a ISRCTN: ISRCTN20579216 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. | ||
| 520 | |a OBJECTIVES: About 6% of the UK general practice population has a record of a penicillin allergy but fewer than 10% of these are likely to be truly allergic. In the ALABAMA (Allergy Antibiotics and Microbial resistance) feasibility trial, primary care patients with penicillin allergy were randomised to penicillin allergy assessment pathway or usual care to assess the effect on health outcomes. A behavioural intervention package was developed to aid delabelling. This study aimed to investigate patients' and clinicians' views of penicillin allergy testing (PAT) | ||
| 520 | |a DESIGN: We conducted a mixed-methods process evaluation embedded within the ALABAMA trial, which included a clinician survey, a patient survey (at baseline and follow-up) and semistructured interviews with patients and clinicians | ||
| 520 | |a SETTINGS: The study was conducted in primary care, as part of the feasibility stage of the ALABAMA trial | ||
| 520 | |a PARTICIPANTS: Patients and primary care clinicians | ||
| 520 | |a RESULTS: Clinicians (N=53; 52.2%) were positive about PAT and its potential value but did not have previous experience of referring patients for a PAT and were unsure whether patients would take penicillin after a negative allergy test. Patients (N=36; 46%) were unsure whether they were severely allergic to penicillin and did not fear a severe allergic reaction to penicillin. Clinician interviews showed that they were already aware of the benefit of PAT. Interviews with patients suggested the importance of safety as patients valued having numerous opportunities to address their concerns about safety of the test | ||
| 520 | |a CONCLUSIONS: This study highlights the positive effects of the ALABAMA behavioural intervention for both patients and clinicians | ||
| 520 | |a TRIAL REGISTRATION NUMBER: NCT04108637; ISRCTN20579216; Pre-results | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a immunology | |
| 650 | 4 | |a primary care | |
| 650 | 4 | |a qualitative research | |
| 650 | 7 | |a Penicillins |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Santillo, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Galal, Ushma |e verfasserin |4 aut | |
| 700 | 1 | |a Davoudianfar, Mina |e verfasserin |4 aut | |
| 700 | 1 | |a Bongard, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Savic, Sinisa |e verfasserin |4 aut | |
| 700 | 1 | |a Savic, Louise |e verfasserin |4 aut | |
| 700 | 1 | |a Porter, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Fielding, Joanne |e verfasserin |4 aut | |
| 700 | 1 | |a Butler, Christopher C |e verfasserin |4 aut | |
| 700 | 1 | |a Pavitt, Sue |e verfasserin |4 aut | |
| 700 | 1 | |a Sandoe, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Tonkin-Crine, Sarah |e verfasserin |4 aut | |
| 700 | 0 | |a ALABAMA team |e verfasserin |4 aut | |
| 700 | 1 | |a Boards, Jenny |e investigator |4 oth | |
| 700 | 1 | |a Bongard, Emily |e investigator |4 oth | |
| 700 | 1 | |a Butler, Christopher C |e investigator |4 oth | |
| 700 | 1 | |a Davoudianfar, Mina |e investigator |4 oth | |
| 700 | 1 | |a East, Mandy |e investigator |4 oth | |
| 700 | 1 | |a Fielding, Joanne |e investigator |4 oth | |
| 700 | 1 | |a Howard, Philip |e investigator |4 oth | |
| 700 | 1 | |a Pavitt, Sue H |e investigator |4 oth | |
| 700 | 1 | |a Porter, Catherine E |e investigator |4 oth | |
| 700 | 1 | |a Sandoe, Jonathan At |e investigator |4 oth | |
| 700 | 1 | |a Santillo, Marta |e investigator |4 oth | |
| 700 | 1 | |a Savic, Louise |e investigator |4 oth | |
| 700 | 1 | |a Savic, Sinisa |e investigator |4 oth | |
| 700 | 1 | |a Shinkins, Bethany |e investigator |4 oth | |
| 700 | 1 | |a Tonkin-Crine, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Wanat, Marta |e investigator |4 oth | |
| 700 | 1 | |a West, Robert |e investigator |4 oth | |
| 700 | 1 | |a Yu, Ly-Mee |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ open |d 2012 |g 12(2022), 6 vom: 03. Juni, Seite e057471 |w (DE-627)NLM215724372 |x 2044-6055 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:6 |g day:03 |g month:06 |g pages:e057471 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmjopen-2021-057471 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 6 |b 03 |c 06 |h e057471 | ||